Boehringer Ingelheim and MD Anderson Partner to Form Virtual R&D Center to Rapidly Advance New Cancer Therapies

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have  announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations. The partnership is built on a flexible framework, allowing for projects to enter at different stages (research, development and/or clinical stage) over several years. It further combines the unique patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division with the innovative pipeline of novel medicines from Boehringer Ingelheim. Learn More